Company Analysis
Sign in

Wave Life Sciences Ltd. (WVE)

Nasdaq: WVE · Pharmaceutical Preparations · Singapore, SG · filing with the SEC since 2015
Full chart Alerts Compare
Grade6.1
◀ Past 5.9● Present 6.6▶ Future 5.6
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Wave Life Sciences Ltd.

Nine metrics read from its own filings, by tense
Headline grade
6.1/10
◀ Past5.930% of the headline
● Present6.640% of the headline
▶ Future5.630% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

5.9/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
8.2/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 33% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

Wave Life Sciences Ltd.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
4.9/10

What has it actually done, year after year?

+50.3% a year over 10 filed years; profitable in 0 of 10.

weight 45% of this tense · 49th percentile among 323 sector filers · read for its customers

From the record

Wave Life Sciences Ltd.'s 10 filed years say what it did: revenue went from $1 million in fiscal 2016 to $43 million in fiscal 2025, up 50.3% a year; it rose in 6 of 9 years; the deepest fall was 91% from fiscal 2021 to fiscal 2022; net income was positive in 0 of 10 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span50.3%top 25% of its family
  • the share of years revenue rosetop 41% of its family
  • the share of filed years with a profitbottom 27% of its family
  • the deepest fall from a revenue peak91.1%bottom 34% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
4.3/10

How has it treated the people who own it?

SI estimate 4.3/10, confidence 35 of 100 (one part).

weight 22% of this tense · 44th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 44% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Wave Life Sciences Ltd.'s shareholder treatment is put at 4.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 44% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

6.6/1040% of the headline grade · 3 of 3 filed

Financial health

as filed
5.9/10

Is it financially healthy right now?

ROE -39%: lost 39¢ per shareholder dollar. Leverage 19%: owes 19¢ per asset dollar.

weight 45% of this tense · 59th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Wave Life Sciences Ltd. lost about 39 cents for every dollar of shareholders' money. Leverage: it owed about 19 cents per dollar of assets, and net share issuance: its share count grew 22.0% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 30% of its family
  • return on equitytop 42% of its family
  • the share count against the year beforebottom 48% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
6.0/10

How strong is its position in its industry?

top 40% of 315 in its family; net margin -478.3%.

weight 33% of this tense · 60th percentile among 315 sector filers · read for its customers

From the record

Wave Life Sciences Ltd.'s standing among 315 graded names in its industry family: revenue of $43 million in fiscal 2025 ranks in the top 47% by size; a net margin of -478.3% ranks in the bottom 38%; revenue growth of 127% a year over the last 3 filed years ranks in the top 10% (its annual reports).

What it rests on

  • revenue against the family$42.7Mtop 47% of its family
  • net margin-478.3%bottom 38% of its family
  • three-year revenue growth127.0%top 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
8.9/10

What are the people in charge doing?

top 11% of 315 in its family for leadership; chief executive since 2015.

weight 22% of this tense · 89th percentile among 315 sector filers · read for its shareholders

From the record

Wave Life Sciences Ltd.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Bolno, Paul (President and CEO, as filed), filing under that title since 2015-11-10, 11 years (top 14% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 10 years (top 8%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (top 10%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge2 in three years among 15 peopletop 10% of its family
  • the median years the people in charge have filed10.0 yearstop 8% of its family
  • the chief executive's years on the record11.0 yearstop 14% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

5.6/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed
6.7/10

How much room does it have to grow?

top 33% of 273 in its family for room to expand.

weight 45% of this tense · 67th percentile among 273 sector filers · read for itself

From the record

Wave Life Sciences Ltd.'s room to grow, from the newest filed statements (fiscal 2025): cash of $602 million against no long-term debt tagged leaves 94.3% of its assets as net cash, top 5% of its family; cash from operations less capital spending is -440.5% of revenue (bottom 36%); research spending of 427.8% of revenue (top 31%) (its annual report).

What it rests on

  • cash less debt against assets94.3%top 5% of its family
  • cash from operations less capital spending against revenue-440.5%bottom 36% of its family
  • research spending against revenue427.8%top 31% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
5.6/10

What could actually drive growth from here?

top 44% of 306 in its family for growth drivers.

weight 33% of this tense · 56th percentile among 306 sector filers · read for its customers

From the record

Wave Life Sciences Ltd.'s growth drivers, from the filed years to fiscal 2025: revenue grew 127% a year over the last three filed years against 50.3% over all 10, speeding up (top 6% of its family); the newest year grew -60.6% (bottom 13%); research spending grew 16.4% a year (top 28%); capital spending grew -19.2% a year (bottom 45%) (its annual reports). Wave Life Sciences Ltd. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span+76.7 points a yeartop 6% of its family
  • the newest year's revenue growth-60.6%bottom 13% of its family
  • three-year growth of research spending16.4%top 28% of its family
  • three-year growth of capital spending-19.2%bottom 45% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
3.5/10

Did its newest year beat what its own record pointed to?

bottom 35% of 233 in its family for expectations against reality.

weight 22% of this tense · 35th percentile among 233 sector filers · read for its shareholders

From the record

Wave Life Sciences Ltd.'s newest year against its own record: revenue of $43 million in fiscal 2025 came in 92.7% below the $589 million its prior three years' pace pointed to (bottom 5% of its family); net income of $204 million against a prior three-year average of $105 million (bottom 15%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 14%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace-92.7%bottom 5% of its family
  • net income against the prior three years' average-94%bottom 15% of its family
  • net margin against its prior averageup more than 100 pointstop 14% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton WVE · research, not advice